

Contents

Preface	iii
1. Introduction	1
1.1 History of Bioavailability Studies	1
1.2 Formulations and Routes of Administration	4
1.3 Pharmacokinetic Parameters	5
1.4 Clinically Important Differences	11
1.5 Assessment of Bioequivalence	12
1.6 Decision Rules and Regulatory Aspects	14
1.7 Statistical Considerations	17
1.8 Aims and Structure of the Book	21
2. Designs of Bioavailability Studies	23
2.1 Introduction	23
2.2 The Study Objective	24
2.3 Basic Design Considerations	26
2.4 The Parallel Design	28
2.5 The Crossover Design	29
2.6 The Balanced Incomplete Block Design	43
2.7 The Selection of Design	46
	vii

3. Statistical Inferences for Effects from a Standard 2 × 2 Crossover Design	48
3.1 Introduction	48
3.2 The Carry-Over Effects	50
3.3 The Direct Drug Effect	52
3.4 The Period Effect	56
3.5 The Analysis of Variance	59
3.6 An Example	63
4. Statistical Methods for Average Bioavailability	70
4.1 Introduction	70
4.2 The Confidence Interval Approach	72
4.3 The Methods of Interval Hypotheses Testing	88
4.4 Bayesian Methods	93
4.5 Nonparametric Methods	109
4.6 Discussion and Other Alternatives	119
5. Power and Sample Size Determination	126
5.1 Introduction	126
5.2 Hypotheses and Type I and Type II Errors	127
5.3 Power and Relative Efficiency	134
5.4 Sample Size Determination	154
6. Transformation and Analysis of Individual Subject Ratios	162
6.1 Introduction	162
6.2 Multiplicative (or Log-Transformed) Model	163
6.3 Bioequivalence Measures	164
6.4 Maximum Likelihood Estimator	166
6.5 Minimum Variance Unbiased Estimator	168
6.6 Mean of Individual Subject Ratios	169
6.7 Ratio of Formulation Means	172
6.8 Comparison of MLE, MVUE, MIR, and RM	175
6.9 An Example	180
6.10 Discussion	184
7. The Assessment of Inter- and Intra-Subject Variabilities	186
7.1 Introduction	186
7.2 Variability and Decision-Making	187
7.3 Point and Interval Estimates	189

7.4	Tests for Equality of Variabilities	195
7.5	Equivalence in Variability of Bioavailability	204
7.6	CV Assessment	211
7.7	Discussion	214
8.	Assumptions and Outliers Detection	217
8.1	Introduction	217
8.2	Tests for Assumptions	218
8.3	The Definition of Outlying Observations	231
8.4	Detection of Outlying Subjects	235
8.5	Detection of Outlying Observations	245
8.6	Discussion	251
9.	Optimal Crossover Designs for Two Formulations	253
9.1	Introduction	253
9.2	Balaam's Design	254
9.3	The Two-Sequence Dual Design	263
9.4	Optimal Four-Period Designs	272
9.5	Transformation and Individual Subject Ratios	284
9.6	Discussion	286
10.	Assessment of Bioequivalence for More than Two Formulations	289
10.1	Introduction	289
10.2	Assessment of Average Bioavailability with More than Two Formulations	290
10.3	Analysis for Williams Designs	295
10.4	Analysis for Balanced Incomplete Block Design	308
10.5	Discussion	311
11.	Assessment of Bioequivalence for Drugs with Negligible Plasma Levels	317
11.1	Introduction	317
11.2	Design and Clinical Endpoints	317
11.3	Statistical Considerations	319
11.4	Weighted Least Squares Method	324
11.5	Log-Linear Models	331
11.6	Generalized Estimating Equations (GEEs)	335
11.7	Analysis of Time to Onset of a Therapeutic Response	338
11.8	Discussion	341

12. Some Related Problems in Bioavailability Studies	343
12.1 Introduction	343
12.2 Drug Interaction Study	344
12.3 Dose Proportionality Study	349
12.4 Steady State Analysis	356
12.5 Population Pharmacokinetics	359
References	361
Appendix A: Statistical Tables	371
Appendix A.1 Areas of Upper Tail of the Standard Normal Distribution	373
Appendix A.2 Upper Quantiles of a χ^2 Distribution	374
Appendix A.3 Upper Quantiles of a Central t Distribution	376
Appendix A.4 Upper Quantiles of an F Distribution	377
Appendix A.5 Upper Quantiles of the Distribution of Wilcoxon-Mann-Whitney Statistic	385
Appendix B: SAS Programs	391
Appendix B.1 Procedures for Average Bioavailability	393
Appendix B.2 Bayesian Method by Grieve	402
Appendix B.3 MVUE, MLE, RI, MIR for a 2×2 Crossover Design	404
Appendix B.4 Parametric and Nonparametric Versions of Pitman-Morgan Test	407
Index	411